Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TGI-5 Monotherapy and in Combination With Nivolumab in Advanced Solid Tumors
NCT07376707Phase 1Recruiting
- Sponsor
- Hefei TG ImmunoPharma Co., Ltd.
- Start
- Jun 2025
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of TGI-5 in solid tumor, colorectal cancer (CRC), melanoma and 2 more (2 arms), sponsored by Hefei TG ImmunoPharma Co., Ltd. Primary endpoints: Dose-limiting Toxicity at 28 days and Frequency and Severity of Adverse Events. Started Jun 2025; status: recruiting.
02
Drugs
TGI-5
03
Conditions
solid tumorcolorectal cancer (CRC)melanomahepatocellular carcinoma (HCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07376707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07376707.